Skip to content

Clinical trials

Breast Neoplasms trials in China with unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Breast Neoplasms Status: Unknown status Country / region: China Clear all

455 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20031
20061
20072
20084
20093
20106
201115
201214
201315
201423
201528
201630
201721
201825
201955
202047
202153
202252
202337
202423

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status455

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fudan University58
Chinese Academy of Medical Sciences29
Peking Union Medical College Hospital25
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University22
Tianjin Medical University Cancer Institute and Hospital17
Sun Yat-sen University16
Zhejiang Cancer Hospital13
Cancer Institute and Hospital, Chinese Academy of Medical Sciences12
Peking University People's Hospital11
The First Affiliated Hospital with Nanjing Medical University10

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Breast Neoplasms455
Lung Neoplasms16
Triple Negative Breast Neoplasms14
Pancreatic Neoplasms11
Brain Neoplasms10
Colorectal Neoplasms10
Neoplasm Metastasis9
Liver Neoplasms8
Ovarian Neoplasms8
Stomach Neoplasms8

Trials

Showing 1 to 25 of 455. Each trial links to its page on Pharma Observatory.

355 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.